Browse all 652 ETFs by category, no search needed
Global 186
US market 62
Country 93
Core UCITS 15
Sector 103
Style & factor 111
Theme 45
Dividend 37
Fidelity Disruptive Medicine (FMED)Overvalued or undervalued?
Look-through valuation · Global · Expense ratio 0.50 % · ISIN US3160921470
Price history (since 2023)
Monthly close since 2023. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| 10X Genomics Inc TXG | 5.2 % | −69.0 % | 65 |
| Natera Inc NTRA | 4.4 % | −94.4 % | 40 |
| Thermo Fisher Scientific Inc TMO | 4.1 % | +3.5 % | 62 |
| Danaher Corporation DHR | 3.8 % | −6.1 % | 72 |
| Illumina Inc ILMN | 3.7 % | +9.0 % | 81 |
| Lifestance Health Group Inc LFST | 3.0 % | −93.4 % | 63 |
| argenx NV ADR ARGX | 2.9 % | +13.1 % | 71 |
| Sartorius Stedim Biotech SA DIM | 2.8 % | −74.7 % | 48 |
| Revolution Medicines Inc RVMD | 2.8 % | n/a | n/a |
| Moderna Inc MRNA | 2.5 % | n/a | n/a |
| Heartflow, Inc. Common Stock HTFL | 2.5 % | n/a | n/a |
| Intuitive Surgical Inc ISRG | 2.2 % | −17.4 % | 75 |
| Alnylam Pharmaceuticals Inc ALNY | 2.2 % | −2.7 % | 68 |
| Vaxcyte Inc PCVX | 2.0 % | n/a | n/a |
| Cogent Biosciences Inc UMRX | 2.0 % | n/a | n/a |
| Kiniksa Pharmaceuticals Ltd KNSA | 1.9 % | −80.7 % | 57 |
| West Pharmaceutical Services Inc WST | 1.9 % | −62.9 % | 71 |
| BrightSpring Health Services, Inc. Common Stock BTSG | 1.9 % | −58.7 % | 48 |
| Kymera Therapeutics Inc KYMR | 1.8 % | n/a | n/a |
| Caris Life Sciences, Inc. Common Stock CAI | 1.7 % | −76.3 % | 59 |
| Repligen Corporation RGEN | 1.7 % | −54.8 % | 67 |
| Ascendis Pharma AS ASND | 1.7 % | −84.8 % | 55 |
| Edwards Lifesciences Corp EW | 1.7 % | −3.9 % | 67 |
| Veeva Systems Inc Class A VEEV | 1.7 % | +7.9 % | 72 |
| Guardant Health Inc GH | 1.7 % | n/a | n/a |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 48 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +76.9 % below FV
- 2 MCHI iShares MSCI China ETF +41.9 % below FV
- 3 ITB iShares U.S. Home Construction ETF +37.1 % below FV
- 4 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +32.2 % below FV
- 5 VOX Vanguard Communication Services Index Fund ETF Shares +21.5 % below FV
- 6 XLC Communication Services Select Sector SPDR® Fund +20.6 % below FV
- 7 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +19.1 % below FV
- 8 FDNI First Trust Dow Jones International Internet ETF +15.2 % below FV
- 9 SHRY First Trust Bloomberg Shareholder Yield ETF +14.6 % below FV
- 10 TAN Invesco Solar ETF +14.5 % below FV
Frequently asked about FMED
Is FMED overvalued?
What is the fair value of FMED?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of FMED?
What is the expense ratio of FMED?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives Fidelity Disruptive Medicine ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Oct 15, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.